COMMUNIQUÉS West-GlobeNewswire

Alpha Tau Treats First Patient with Recurrent Lung Cancer
10/10/2024
JERUSALEM, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ® , announced today [...]
Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics
10/10/2024
DOYLESTOWN, Pa., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic [...]
Femasys to Exhibit at ASRM 2024 and Participate in the Congress’ KEEPR Education Program
10/10/2024
Company’s VP of Education and Global Training Named Chairman of ASRM Corporate Member Council ATLANTA, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing [...]
Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC)
10/10/2024
– Company has received a No Objection Letter from Health Canada in response to submission of its Phase 1 Clinical Trial Application (CTA) – The study is a Phase 1 Single Ascending Dose (SAD) /Multiple Ascending Dose ( [...]
SI-BONE, Inc. Announces First-In-Patient Procedures with FDA Breakthrough Device for Pelvic Fracture Fixation
10/10/2024
SANTA CLARA, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to providing surgical solutions for sacropelvic disorders, today announced [...]
Clearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical Site
10/10/2024
FDA approval for the IND submission to conduct its trial already secured Vancouver, Canada, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a [...]
MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer
10/10/2024
ROCKVILLE, Md., Oct. 10, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and [...]
Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement
10/10/2024
Boston (October 10, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that [...]
Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit
10/10/2024
Media Release SYDNEY, AUSTRALIA, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for [...]
Construction of JinMed's New Facility Begins in Chuzhou, China
10/10/2024
Chuzhou City, China, Oct. 10, 2024 (GLOBE NEWSWIRE) -- JIN MEDICAL INTERNATIONAL LTD. (the "Company" or “JinMed”) (NASDAQ: ZJYL), an industrial leader in Assistive Technologies (“AT”), and a manufacturer and developer [...]
Bionano Announces Preliminary 3Q 2024 Revenues and Cash
10/10/2024
SAN DIEGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced select preliminary results for the quarter ended September 30, 2024. The Company now expects revenue for the third [...]
Information on the total number of voting rights and shares
09/10/2024
REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), October 9, 2024 , 10:35 pm CET / 4:35 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the [...]
Informations sur le nombre total de droits de vote et d'actions
09/10/2024
INFORMATION RÉGLEMENTÉE Informations sur le nombre total de droits de vote et d'actions Mont-Saint-Guibert (Belgique), le 9 octobre 2024, 22:35h CET / 16:35h ET – Conformément à l'article 15 de la loi du 2 mai 2007 [...]
Kairos Pharma to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
09/10/2024
LOS ANGELES, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced today that John S. Yu, M.D., Chief Executive Officer, will participate in a [...]
Publication relating to transparency notifications
09/10/2024
REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), October 9, 2024 , 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the [...]
Publication relative à des notifications de transparence
09/10/2024
INFORMATION RÉGLEMENTÉE Publication relative à des notifications de transparence Mont-Saint-Guibert (Belgique), le 9 octobre 2024 , 22:30h CET / 16:30h ET – Conformément à l'article 14 de la loi du 2 mai 2007 relative à [...]
Certara to Report Third Quarter 2024 Financial Results on November 6th, 2024
09/10/2024
RADNOR, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the third quarter of 2024 after [...]
ORIC® Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
09/10/2024
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of [...]
Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit
09/10/2024
WESTLAKE VILLAGE, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick , President, CEO and Chairman of the [...]

Pages